Molecular Oncology (Feb 2022)

Epigenetic readers and lung cancer: the rs2427964C>T variant of the bromodomain and extraterminal domain gene BRD3 is associated with poorer survival outcome in NSCLC

  • Jang Hyuck Lee,
  • Seung Soo Yoo,
  • Mi Jeong Hong,
  • Jin Eun Choi,
  • Hyo‐Gyoung Kang,
  • Sook Kyung Do,
  • Won Kee Lee,
  • Sun Ha Choi,
  • Yong Hoon Lee,
  • Hyewon Seo,
  • Jaehee Lee,
  • Shin Yup Lee,
  • Seung Ick Cha,
  • Chang Ho Kim,
  • Eung Bae Lee,
  • Sukki Cho,
  • Sanghoon Jheon,
  • Jae Yong Park

DOI
https://doi.org/10.1002/1878-0261.13109
Journal volume & issue
Vol. 16, no. 3
pp. 750 – 763

Abstract

Read online

Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate gene expression. We investigated whether variants in BET genes are associated with survival outcomes for lung cancer. To do this, the associations between 77 variants in BET family genes and survival outcomes were analyzed in 773 non‐small‐cell lung cancer (NSCLC) patients who underwent surgery (349 and 424 patients in the discovery and validation cohorts, respectively). We found that six variants were significantly associated with overall survival (OS) in the discovery cohort, and one variant (rs2506711C>T) was replicated in the validation cohort. BRD3 rs2506711C>T is located in the repressed area and has a strong linkage disequilibrium with rs2427964C>T in the promoter region. BRD3 rs2427964C>T was significantly associated with worse OS in the discovery cohort, validation cohort, and combined analysis. In a luciferase assay, promoter activity in the BRD3 rs2427964 T allele was significantly higher than that in the BRD3 rs2427964 C allele, which selectively bound with the transcriptional repressor SIN3A. Knockdown of BRD3 with BRD3‐specific siRNA decreased the proliferation and migration of lung cancer cells while also increasing the rate of apoptosis. These results suggest that BRD3 rs2427964C>T increases BRD3 expression through increased promoter activity, which is associated with poor prognosis for lung cancer.

Keywords